// App-Quantinova.ai

CT152 : First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers

Researchers

Presenter

  • Laurence Buisseret

Principal Investigators

  • Sylvie Rottey

  • Johann de Bono

  • Manon Mossakowski

  • Brant Delafontaine

  • Thubeena Manickavasagar

  • Nuria Kotecki

  • Chiara Martinoli

  • Manfred Schneider

  • Olivier De Henau

  • Patricia Chevron

  • Joanne Lager

  • Jean-Pascal Machiels

Medical Centers

  • Dermatology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium,

  • Department of Medical Oncology, Drug Research Unit Ghent, Universitair Ziekenhuis Ghent, Ghent, Belgium

  • Division of Clinical Studies, The Institute of Cancer Research, Royal Marsden National Hospital Trust, Sutton, United Kingdom

  • Pediatric Endocrinology Unit, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Brussels, Belgium

  • Dermatology Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium,

  • iTeos Therapeutics, Gosselies, Belgium

  • Neon Therapeutics, Inc., Cambridge, MA

  • Department of medical oncology and head and neck surgery, Cancer center, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Experimentale (Pole MIRO), Universite catholique de Louvain, Brussels, Belgium

Locations

  • Belgium

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Endometrial Cancer

  • Unspecified Cancer

  • Solid malignancies

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Adenosine

  • Adenosine Intravenous

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Multicenteric

  • First-In-Human

Phase

  • I

Study Id's

  • NCT02740985

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved